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Molecular markers relevant to myocardial injury following
dental extraction in patients with and without coronary
artery disease
K. M. Habbab1,2, F. D’Aiuto1, M. A. Habbab2 and S. R. Porter1
OBJECTIVES: The aim of this study was to characterize biological changes following dental extractions in patients with and without
coronary artery disease (CAD).
MATERIALS AND METHODS: Forty-five patients (36 males and 9 females) referred for dental extraction underwent treatment and
provided blood samples before, immediately after, and 24 h after the procedure. A broad array of biomarkers was employed to
assess myocardial injury (highly sensitive troponin T, hs-TnT), bacterial burden (LPS endotoxin activity), and systemic inflammation
(CRP, fibrinogen, IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-12, and TNF-α).
RESULTS: Dental extraction in patients with and without CAD was associated with rises in hs-TnT (p= 0.013), hs-CRP (p < 0.001),
fibrinogen (p= 0.005), endotoxin activity (p < 0.001), IFN-γ (p < 0.001), IL-6 (p < 0.001), IL-8 (p= 0.011), and IL-12 (p < 0.001) at 24 h
compared with immediately post procedure. Changes in systemic inflammation and endotoxin activity were more evident in those
with hs-TnT rise.
CONCLUSIONS: Simple dental extractions may cause mild increase in hs-TnT, indicating minor myocardial injury in both patients
with and without CAD. Acute systemic inflammation and endotoxemia could represent a possible link between invasive dental
treatment and increased risk of acute cardiovascular events. These findings indicate that invasive dental treatment (as simple as a
single dental extraction) may impact negatively on clinical outcomes in dental patients, especially those with CAD.
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INTRODUCTION
Inflammation plays a major role in the pathogenesis of athero-
sclerosis and its complications.1 Peri-procedural minor myocardial
injury related to systemic inflammation following coronary
interventions can worsen the clinical outcome of patients with
coronary artery disease (CAD).2,3
Poor oral health, especially in the form of periodontitis, is
known to cause an elevation of inflammatory biomarkers, and its
treatment has been linked with both acute and chronic changes in
systemic inflammation in otherwise healthy individuals.4 A recent
case series reported an increased risk of mortality, due to vascular
events in patients with CAD following dental treatment.5
Epidemiologic evidence links invasive dental procedures with an
increased risk of vascular events, but the mechanisms that
underlie these trends remain poorly understood.6 The acute
influence of invasive dental procedures, such as exodontia upon
CAD, and the possible mechanisms involved, have not been
described in great detail.
Invasive periodontal treatment (nonsurgical and surgical
therapy) as well as the third molar extraction cause increases in
circulating markers of inflammation, coagulation, and endothelial
cell activation in 7 days following treatment.7–9 These acute
changes are also associated with a transient state of vascular
dysfunction and pro-coagulant state,8 but have yet to be linked to
increased mortality or clinical events in patients (healthy or with
CAD). Bacteremia following exodontia and other dental
treatments10 may cause myocardial ischemia by a variety of
possible mechanisms.11–19 In addition, tissue injury caused by
local surgical trauma is known to trigger a systemic inflammatory
and pro-coagulant state.20–22
All of the above mechanisms might add to the inflammatory
burden of patients with CAD and have a direct influence on
vulnerable coronary atherosclerotic plaques, leading to plaque
fissuring/rupture, thrombogenesis, and/or microembolization
within the myocardium, leading to microinfarcts and minor
myocardial injury.23,24
The aim of this study was to characterize biomarker changes
relevant to myocardial injury, following invasive dental procedures
(predominantly dental extractions) in patients with and without
coronary artery disease. Changes in circulating biomarkers of
myocardial ischemia, endotoxemia, and systemic inflammation
were determined before and after the invasive dental procedures.
MATERIALS AND METHODS
Study design and patient population
In this prospective clinical study, we enrolled forty-five consecu-
tive adult patients (36 men and 9 women) referred to the Special
Care Dentistry Unit of the University College Hospital NHS
Foundation Trust (UCLHT) Eastman Dental Hospital or UCLHT
Heart Hospital for routine pre-cardiac surgery dental assessment/
treatment. Participants were categorized into two groups, patients
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with and patients without CAD, by history and the available results
of coronary angiography, echocardiography, or ECG. All patients in
the CAD group had evidence of CAD by coronary angiography.
Eligible participants were excluded if immunocompromised (e.g.,
organ transplant or taking immunosuppressants), had episodes of
acute inflammation, or had a diagnosed chronic immune or
inflammatory disease (assessed by the examining cardiologist). All
patients gave informed consent and the study was approved by
the National Research Ethics Service (reference number, 10/
H0715/42).
Dental examination and therapy
After a baseline visit and collection of a complete medical and
dental history (assessed by interview), dental status (i.e.,
decayed, missing, and filled teeth), oral mucosal health, and
clinical periodontal parameters were recorded by a single
trained clinician. All participants needed dental extractions. A
single operator performed all dental treatment. A topical
analgesic gel (lidocaine 2%) was applied over the site of
injection of the local anesthetic. Local anesthetic (1.8 ml of
articaine HCl 4% with 1:1,00,000 epinephrine carpule) was
injected into the site of the tooth (or teeth) of concern. The
number of carpules used was determined on a case-by-case
basis according to the site of the teeth in concern, the number
of the teeth, and the patient’s perception to pain. According to
the current National Institute for Health and Care Excellence
(NICE) guidelines,25 patients at risk of infective endocarditis
were not given antibiotic prophylaxis prior to the dental
treatment, unless specifically recommended by their cardiolo-
gist. When recommended (in one patient from the CAD and five
from the non-CAD group), antibiotic prophylaxis was adminis-
tered according to the 2006 British Society of Antimicrobial
Chemotherapy (BSAC) guidelines26 (3 g of oral amoxicillin
administered 1 h prior to the procedure or 600 mg of oral
clindamycin if the patient was allergic to penicillin).
Sample collection and analysis
Non-fasting blood samples were obtained by a clean venipuncture
from the antecubital fossa and with minimal stasis, before and 15
min and 24 h after the dental procedures. Plasma was immediately
processed and stored in several aliquots at −70 °C for later
analysis. Analysis performed at 48 h following dental extraction
did not demonstrate any significant changes of most routine
hematological and chemical blood tests.27
Biomarkers of myocardial injury. High-sensitivity cardiac troponin
T (hs-TnT) was quantified according to the manufacturer’s
protocol in a blind fashion, using electrochemiluminiscence
immunoassay (Cobas, Roche Diagnostic, Mannheim, Germany)
with a detection limit of 3.0 ng/L. Since the study involved patients
undergoing simple extractions, the main aim was to check for any
rise in hs-cTnT, as a link between dental procedures and acute
cardiovascular events and not to demonstrate a rise above a
certain level to diagnose myocardial infarction, which is not
expected with such procedures.
Biomarkers of systemic inflammation. A broad panel of inflam-
matory biomarkers was measured by a multiplex high-sensitivity
assay, including interleukin-1β (IL-1β), IL-6, IL-8, IL-10, IL-12,
interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) (Meso
Scale Discovery, Maryland, USA). Serum C-reactive protein (CRP)
was measured by immunoturbidometry (Cobas, Roche Diagnostic,
Mannheim, Germany).
Endotoxin activity. Lipopolysaccharide (LPS) endotoxin activity
was measured by a zymogenic assay, according to the manufac-
turer's instructions (Endpoint Chromogenic Limulus Amebocyte
Lysate, LAL Test, Lonza, Walkersville, Maryland, USA).
Statistical analysis
All data are presented as mean and standard error of the mean
unless specified. Demographic data at baseline were compared
between groups at baseline (CAD and not CAD groups) by paired
t-test for numerical variables and Fisher’s exact test for categorical
variables. As no previous evidence was identified, the sample size
calculation was based on a hypothetical difference in hs-cTn of
1 ng/ml between study groups (CAD and not CAD) after 24 h (SD
of 1, power 90%), resulting in a N= 23 per group. Since this work
represents a proof-of-concept study, no power calculation was
performed. Because of the multiple variables to be analyzed and
overcome the danger of obtaining spuriously significant results
due to multiple testing, paired t tests were performed on all
variables to compare different time points within each group. Only
those variables that were found significant at the 0.05 level were
analyzed using a hierarchical analysis of variance (ANOVA) with
patients nested in groups and repeated measures over time. Post
hoc Bonferroni comparisons were made to compare mean values
at different time points in the ANOVA and a significance level of
0.025 was chosen instead of the conventional 0.05 to avoid
spuriously significant results due to multiple testing. To assess the
effect of any covariate that was distributed differently at baseline
in the two groups, a regression analysis was performed with the
outcome variable being the change in the variable of interest from
one time point to the next and the explanatory variables being
group, the significant demographic variable, and the interaction
between the two. Following analysis of the primary marker (hs-
TnT), the study sample was then categorized in two groups based
on whether hs-TnT increased at 24 h or not. Data were graphically
tested for normality, and logarithmic or square root transforma-
tions were made as needed before applying the adequate
nonparametric tests. All analysis was performed with the statistical
software package SPSS 21 (SPSS Inc., Chicago, IL, USA).
RESULTS
Study patients at baseline (with and without CAD)
The CAD group comprised 28 patients (25 men and 3 women)
with an age range of 41–91 years and the non-CAD group
comprised 17 patients (11 men and 6 women) with an age range
of 38–80 years. All patients attended the 24 -h visit follow-up and
provided blood samples. There were no significant statistical
differences between patients with and without CAD in terms of
patient’s characteristics, associated diseases/risk factors, dental
procedure-related variables, and medications used by the
patients, except for antibiotic cover (3.6% in the CAD group and
29.4% in the non-CAD group, p= 0.023) (Table 1). The mean ±
SEM values of biomarkers of all study patients and of patients with
and without CAD at the three time points (pre, immediately post,
and day 1 after treatment) are shown in Table 2.
Myocardial injury. Statistically significant changes (p < 0.05) were
observed following dental procedures (Table 2) and ANOVA
analysis showed significant difference (p < 0.025) between two or
more of the time points for hs-TnT (Table 3). However, there was
no statistical significant difference between the groups (CAD vs.
no CAD) or in the interaction between the groups and the
different time points, thus inferring that the change was similar for
both groups (Table 3). Concentrations 24 h after the dental
procedure were substantially higher than those obtained imme-
diately post procedure (Table 3). Graphical studies demonstrated
that hs-cTnT values were normally distributed and changes in the
estimated marginal means are shown in Fig. 1.
Systemic inflammation. Graphical studies of the biomarkers of
systemic inflammation demonstrated that fibrinogen and TNF-α
were normally distributed, while CRP, IFN-α, IL-1β, IL-6, IL-8, and
IL-12 were not; thus, the latter required logarithmic transformation
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before further analysis using ANOVA. Changes in the estimated
marginal means of these markers are shown in Fig. 1. Statistically
significant changes (p < 0.05) were observed following dental
procedures for hs-CRP, fibrinogen, IFN-γ, TNF-α, IL-1β, IL-6, IL-8,
and IL-12 and no differences were noted at any of the time points
for IL-10 (Table 2). Further analysis showed significant difference
(<0.025) between two or more of the time points for hs-CRP,
fibrinogen, IFN-γ, IL-6, IL-8, and IL-12 (Table 3), which were similar
for both groups with and without CAD (Table 3). Concentrations
observed at 24 h after the dental procedure were substantially
higher than those obtained immediately after the procedure for all
these biomarkers and higher than those obtained before the
procedure for CRP, IFN-γ, IL-6, IL-8, and IL-12 (Table 3).
Endotoxemia. Statistical significant changes were observed
following dental procedures for LPS (Table 2) and the kinetics of
this biomarker was similar for both groups with and without CAD
(Table 3). Concentrations were substantially higher 24 h after the
dental procedure than those obtained immediately post proce-
dure (Table 3). Graphical studies demonstrated that LPS endotoxin
values were normally distributed and the changes in the
estimated marginal means are being shown in Fig. 1.
As antibiotic cover was distributed differently at baseline in the
two groups (Table 1), linear regression analysis, including
antibiotic cover into the modeling, demonstrated a significant
effect on the change of IL-6 between pretreatment and 24 h post
treatment, as well as between immediately post treatment and 24
h post treatment, but this effect was not consistent for each study
group. However, only one patient within the CAD group received
antibiotic cover; therefore, detailed statistical analysis of this factor
was not possible.
Patients with and without hs-TnT rise
The hs-TnT rise group comprised 28 patients (22 men and 6
women) with an age range of 51–91 years and the hs-TnT non-rise
group consisted of 17 patients (14 men and 3 women) with an age
range of 38–86 years. There were no significant statistical
differences between the two groups in terms of patient’s
characteristics, associated diseases/risk factors, dental procedure-
related variables, and medications used by the patients (Table 4).
The mean ± SEM values of biomarkers of all study patients and
of patients with and without hs-TnT rise at the three time points
(pre, immediately post, and day 1 after treatment) are shown in
Table 5.
Systemic inflammation. Statistically significant changes were
observed following dental procedures in both groups with and
without hs-cTnT rise for hs-CRP, fibrinogen, IFN-γ, TNF-α, IL-6, IL-8,
and IL-12, and no significant differences were noted for IL-1β and
IL-10 (Table 6). Graphical studies of these biomarkers demon-
strated that fibrinogen and TNF-α were normally distributed, while
CRP, IFN-γ, IL-6, IL-8, and IL-12 were not, and thus required
logarithmic (for CRP, IFN-γ, IL-6, and IL-8) and square root (for IL-
12) transformation before further analysis using ANOVA. Changes
in the estimated marginal means ± SEM of these markers are
shown in Fig. 2.
Endotoxemia. Statistically significant changes for LPS were
observed in both groups following dental procedures (Table 6).
Graphical studies demonstrated that LPS endotoxin values were
normally distributed and changes in the estimated marginal
means ± SEM are shown in Fig. 2.
DISCUSSION
This study confirmed that dental surgery is associated with a rise
in hs-TnT, bacterial LPS endotoxin, and acute systemic inflamma-
tion. These changes were similar in both patients with and without
CAD, although the changes in systemic inflammation and
endotoxemia were more pronounced in those with a rise in hs-
TnT. These findings were independent of age, gender, smoking,
and other traditional cardiovascular risk factors.







Male gender, n (%) 25 (89.3) 11 (64.7) 0.0626
Age, years (mean ± SD) 71.04 ± 10.54 65.94 ± 13.33 0.1906
• Associated diseases/risk factors
Smoking, n (%) 2 (7.1) 3 (17.7) 0.3504
Hypertension, n (%) 18 (64.3) 10 (58.8) 0.7591
Diabetes, n (%) 11 (39.3) 2 (11.8) 0.0881
Chronic renal failure, n (%) 2 (7.1) 0 (0.0) 0.5192
COPD, n (%) 3 (10.7) 0 (0.0) 0.2788
BMI (mean ± SD) 29.61 ± 5.76 27.60 ± 5.57 0.4311
Dental procedure-related variables
Number of extracted teeth
(mean ± SD)
2.18 ± 1.36 2.12 ± 1.41 0.8876
Flap opened, n (%) 12 (42.8) 6 (35.3) 0.7566
Bone removal, n (%) 7 (25.0) 4 (23.5) 1.0000
Number of LA carpules
(mean ± SD)
2.29 ± 0.88 2.21 ± 0.83 0.7612
Oral sedation (20mg of
diazepam), n (%)
10 (35.7) 4 (23.5) 0.5134
Preoperative GTN, n (%) 1 (3.6) 0 (0.0) 1.0000
Antibiotic cover, n (%) 1 (3.6) 5 (29.4) 0.0228
• Medications
Single antiplatelets, n (%) 13 (46.4) 5 (29.4) 0.3523
Dual antiplatelets, n (%) 3 (10.7) 0 (0.0) 0.2788
Beta-blockers, n (%) 18 (64.3) 6 (35.3) 0.0727
Statins, n (%) 19 (67.9) 7 (41.2) 0.1206
Ezetimibe, n (%) 5 (17.6) 0 (0.0) 0.1401
Warfarin, n (%) 7 (25.0) 5 (29.4) 0.7428
ACE inhibitors, n (%) 16 (57.1) 7 (41.2) 0.3651
Calcium channel blockers,
n (%)
7 (25.0) 3 (17.7) 0.7189
Nitrates, n (%) 4 (14.3) 0 (0.0) 0.2812
Cardiac glycosides, n (%) 4 (14.3) 0 (0.0) 0.2812
Proton-pump inhibitors,
n (%)
5 (17.6) 2 (11.8) 0.6932
Diuretics, n (%) 8 (28.6) 7 (41.2) 0.5167
Alpha-1 blockers, n (%) 3 (10.7) 1 (5.9) 1.0000
ARBs, n (%) 1 (3.6) 2 (11.8) 0.5571
Oral hypoglycemics, n (%) 7 (25.0) 3 (17.7) 0.7189
Insulin, n (%) 1 (3.6) 0 (0.0) 1.0000
Seretide inhaler, n (%) 2 (7.1) 0 (0.0) 0.5192
Anticholinergics, n (%) 3 (10.7) 0 (0.0) 0.2788
Beta-2 agonists, n (%) 5 (17.6) 0 (0.0) 0.1401
Antiepileptics, n (%) 2 (7.1) 1 (5.9) 1.0000
Antidepressants, n (%) 4 (14.3) 1 (5.9) 0.6353
ACE inhibitors angiotensin-converting enzyme inhibitors, ARBS angiotensin
receptor blockers, BMI body mass index, COPD chronic obstructive
pulmonary disease, GTN glyceryl trinitrate, LA local anesthetic
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Table 2. Mean levels of biomarkers of all study patients and of patients with and without CAD at the three time points (pre, post, and day 1)
Biomarker Total patientsa CAD patientsb Non-CAD patientsc
Pre Post Day 1 Pre Post Day 1 Pre Post Day 1
• Biomarker of myocardial injury
hs-TnT (ng/L) 16.10 ± 2.42 15.28 ± 2.28 16.43 ± 2.45 17.91 ± 3.38 16.98 ± 3.22 18.34 ± 3.47 13.12 ± 3.18 12.47 ± 3.02 13.29 ± 3.23
• Biomarkers of systemic inflammation
hs-CRP (mg/L) 4.16 ± 0.61 3.96 ± 0.59 9.69 ± 1.44 4.53 ± 0.86 4.38 ± 0.83 9.80 ± 1.85 3.56 ± 0.86 3.28 ± 0.80 9.51 ± 2.31
Fibrinogen (mg/l) 3.29 ± 0.49 3.22 ± 0.48 3.54 ± 0.53 3.20 ± 0.60 3.16 ± 0.60 3.43 ± 0.65 3.45 ± 0.84 3.35 ± 0.81 3.72 ± 0.90
IFN-γ (pg/ml) 2.36 ± 0.35 2.40 ± 0.36 7.59 ± 1.13 2.37 ± 0.45 2.46 ± 0.47 8.06 ± 1.52 2.34 ± 0.57 2.30 ± 0.56 6.82 ± 1.66
TNF-α (pg/ml) 10.52 ± 1.57 10.31 ± 1.54 11.37 ± 1.69 10.76 ± 2.03 10.40 ± 1.97 11.61 ± 2.19 10.12 ± 2,46 10.15 ± 2.46 10.99 ± 2.67
IL-1β (pg/ml) 0.44 ± 0.07 0.39 ± 0.06 0.47 ± 0.07 0.50 ± .0.09 0.39 ± 0.07 0.49 ± 0.09 0.33 ± 0.08 0.39 ± 0.09 0.44 ± 0.11
IL-6 (pg/ml) 1.96 ± 0.29 1.89 ± 0.28 3.92 ± 0.58 2.08 ± 0.39 1.99 ± 0.38 4.15 ± 0.78 1.77 ± 10.43 1.73 ± 0.18 3.54 ± 0.86
IL-8 (pg/ml) 4.25 ± 0.63 5.56 ± 0.83 6.51 ± 0.97 4.51 ± 0.85 5.23 ± 0.99 7.35 ± 1.39 3.83 ± 0.93 6.10 ± 2.09 5.13 ± 1.25
IL-10 (pg/ml) 7.87 ± 1.17 8.28 ± 1.23 8.52 ± 1.27 7.47 ± 1.41 8.07 ± 1.53 8.14 ± 1.54 8.53 ± 2.07 8.62 ± 2.09 9.15 ± 2.22
IL-12 (pg/ml) 7.33 ± 1.09 6.83 ± 1.02 7.45 ± 1.11 4.41 ± 0.83 4.25 ± 0.80 5.22 ± 0.99 12.14 ± 2.95 11.10 ± 2.69 11.13 ± 2.70
• Biomarker of endotoxemia (LPS endotoxin)
LPS (LAL) (EU/ml) 1.02 ± 0.15 1.09 ± 0.16 1.41 ± 0.21 0.98 ± 0.19 1.05 ± 0.20 1.45 ± 0.22 1.08 ± 0.26 1.17 ± 0.28 1.34 ± 0.33
IL interleukin IFN-γ interferon-γ, hs-TnT highly sensitive troponin T, hs-CRP highly sensitive C-reactive protein, LPS lipopolysaccharide,TNF-α tumor necrosis
factor-α
Values=mean ± SEM
an= 45 for all except for fibrinogen= 43
bn= 28 for all except for fibrinogen= 27
cn= 17 for all except for fibrinogen= 16
Table 3. Hierarchical ANOVA and post hoc Bonferroni comparisons performed on hs-TnT, fibrinogen, TNF-α, LPS, and on hs-CRP, IFN-γ, IL-1β, IL-6, IL-
8, and IL-12 after logarithmic transformation in patients with and without CAD
Biomarker P-values between-subject effects using hierarchical
ANOVAa
P-values between different time points using post hoc
Bonferronib
Groupc Timed Group×timee Pre–Postf Pre-D1g Post-D1h
• Biomarker of myocardial injury
hs-TnT 0.227 0.025 0.805 0.118 >0.999 0.013
• Biomarkers of systemic inflammation
hs-CRP log 0.741 <0.001 0.679 >0.999 <0.001 <0.001
Fibrinogen 0.270 0.006 0.835 >0.999 0.038 0.005
IFN-γ log 0.628 <0.001 0.418 >0.999 <0.001 <0.001
TNF-α 0.744 0.046 0.887 >0.999 0.137 0.040
IL-1β log 0.233 0.114 0.957 >0.999 0.352 0.180
IL-6 log 0.328 <0.001 0.672 >0.999 <0.001 <0.001
IL-8 log 0.422 <0.001 0.457 0.027 <0.001 0.011
IL-12 log 0.91 <0.001 0.579 >0.999 <0.001 <0.001
• Biomarker of endotoxemia (LPS endotoxin)
LPS (LAL) 0.612 <0.001 0.151 0.633 <0.001 <0.001
IL interleukin, IFN-γ interferon-γ, hs-TnT highly sensitive troponin T, hs-CRP highly sensitive C-reactive protein, LPS lipopolysaccharide, TNF-α tumor necrosis
factor-α
aHierarchical ANOVA at a significance level of 0.025 performed on biomarkers that were found significant at the 0.05 level by paired t-test after logarithmic
transformation
bPost hoc Bonferroni comparisons made to compare mean values at different time points of the ANOVA
at a significance level of 0.025 (significant difference shown in red)
cGroup= comparing CAD vs. non-CAD patients
dTime= comparing the different time points (pretreatment, immediately post treatment, and day-1 treatment)
eGroup × time= comparing the interaction between the groups and time points
fPre–Post= comparing pretreatment and immediately post treatment
gPre-D1= comparing pre-treatment and day-1 treatment
hPost-D1= comparing immediately post treatment and day-1 treatment
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This study demonstrated for the first time statistically significant
elevations of hs-TnT within 24 h following dental extractions,
irrespective of whether patients had CAD or not. A previous
investigation employing a conventional cTnT assay did not find a
rise in cTnT levels following dental extractions.28 The high-
sensitivity assay used in this study may represent the most
plausible explanation for the differences with our findings.29 While
measurable, the presently observed minute increases in hs-TnT
probably reflect a transitory impairment of myocardial integrity.
This might be due to either increased cellular permeability and
early troponin release from the cytosolic pool during ischemia
(similar to those reported following strenuous exercise)30 or the
consequence of breakdown of myocytes following microthrom-
bosis (similar to that occurring following coronary
interventions)31,32 or a combination of both mechanisms.33 During
cardiac ischemia, cardiac myocytes develop blebs on the surface
of their plasma membrane and release cytoplasmic contents,
without undergoing necrosis.34 Blebs have been defined as
“bubbles” developing from the plasma membrane in response
to temporary ischemia, which can either be resorbed or shed into
the circulation when reoxygenation later occurs. However, when
the ischemia is severe and prolonged (as in ACS), the blebs grow
and collapse, and cell necrosis occurs.34 Reversible ischemia-
induced bleb release is characterized by a brief peak, and a rapid
decrease and normalization within 72 h,35 while irreversible
myocyte necrosis release is characterized by a steep increase
and prolonged elevation for at least 4–7 days.36 Hence, hs-TnT
measurement 4–7 days after the procedure could differentiate
between the two mechanisms. Alternatively, using delayed
enhancement magnetic resonance imaging,37 myocardial micro-
infarction could be verified.38
Fig. 1 Changes in the estimated marginal means ± SEM in CAD patients (red line) and non-CAD patients (green line) of hs-cTnT, inflammation
markers with statistically significant changes (hs-CRP log, fibrinogen, IFN-γ log, TNF-α, IL-1 log, IL-6 log, IL-8 log, and IL-12 log), and LPS
endotoxin
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The clinical significance of the present observations in patients
with CAD remains to be established. Indeed, peri-procedural
minor myocardial injury detected by cardiac troponin following
coronary interventions is associated with a worsened cardiac
outcome of CAD patients.2,3 If proven of clinical significance, the
protocols for even minor invasive dental treatment in patients
with CAD would need to be revisited. Further support for the
present findings comes from the epidemiologic evidence of a
modest but statistically significant increase of acute vascular
events following invasive dental procedures in a large US sample9
and a recent observation of a case-series report of major adverse
outcomes associated with planned exodontia before cardiac
operations.5
Then again, a recent study reported that Medicare beneficiaries
who underwent dental procedures within 30–180 days after an
ischemic vascular event were not at an increased risk of
experiencing a second event.39 However, this report was based
on a combined survey and administrative data set and did not
contain clinical or laboratory diagnostic information. In addition,
the survey recorded many noninvasive dental procedures,
including radiographs, examinations, restorations, crowns, bridges
and complete and removable dentures, orthodontics, and other
services, which are not expected to trigger vascular injury.39
Systemic inflammation
Intensive periodontal treatment (including dental extractions) leads
to transient impaired brachial artery flow-mediated dilation (a
measure of endothelial function) and increased markers of
inflammation and endothelial activation in the first 30 days after
treatment and then followed by a progressive improvement
6 months after baseline.5,7 The more invasive the dental treatment,
the greater the rise in inflammation markers.8 In this investigation, a
large array of inflammatory biomarkers increased following dental
treatment, confirming that a simple dental extraction can trigger a
systemic inflammatory response, possibly due to endotoxemia and
local tissue injury. The rise in hs-TnT in the same patients might
support the involvement of systemic inflammatory response in the
etiology of ischemia/injury observed following coronary interven-
tions in CAD patients,31,32 which is possibly caused by the induction
of thrombogenesis and/or microembolization within the myocar-
dium, leading to microinfarcts.
Bacterial burden
Bacteremia following invasive dental procedures or simple tooth
brushing or even chewing has been previously established.40–47
Collagen-like molecule on the surface of Streptococcus sanguis and
Porphyromonas gingivalis can induce a hypercoagulable state by
increasing serum fibrinogen, white blood cell number, and
platelet aggregation.10–12 The results of this study confirm a
raised endotoxin activity 24 h following dental extraction, which
might explain the induction of a hypercoagulable state and
suggest either a direct pathogen effect at sites distant from the
oral cavity or host inflammatory/immune response.48,49 Low levels
of endotoxin induce inflammatory responses in human monocytes
and macrophages, and vascular smooth muscle cells and intact
human blood vessels also exhibit a profound cytokine release,
superoxide production, and monocyte adhesion in response to
exodontia.15,16 In addition, LPS can significantly decrease fibrous
cap thickness and increase macrophage and lipid contents of
atherosclerotic plaques, which can lead to their disruption.49 In
vivo studies have demonstrated that increased LPS endotoxin
levels due to infection or sepsis can cause apoptosis through the
activation of caspases in myocardial cells via the induction of
proinflammatory acute-phase proteins and cytokines within these
cells, resulting in contractile dysfunction and sarcomeric destruc-
tion that are reflected in an increase in peripheral blood troponin
levels.37,38 The significantly increased levels of LPS endotoxin in
these patients might be associated with similar cellular events,
which may provide another or additional mechanism by which hs-
TnT levels increase following dental extraction.
In summary, this study demonstrated that dental surgery is
associated with potential minor myocardial injury in the form of








Male gender, n (%) 22 (78.6) 14 (82.3) 1.0000
Age, years (mean ± SD) 71.40 ± 9.24 65.35 ± 14.64 0.1400
• Associated diseases/risk factors
Coronary artery disease 17 (60.7) 11 (64.7) 1.0000
Smoking, n (%) 3 (10.7) 2 (11.8) 1.0000
Hypertension 18 (64.3) 10 (58.8) 0.7591
Diabetes, n (%) 7 (25.0) 7 (41.2) 0.3262
Chronic renal failure, n (%) 1 (3.6) 1 (5.9) 1.0000
COPD, n (%) 2 (7.1) 1 (5.9) 1.0000
BMI (mean ± SD) 29.55 ± 5.70 27.93 ± 5.91 0.5209
• Dental procedure-related variables
Number of extracted teeth
(mean ± SD)
2.25 ± 1.38 2±1.37 0.5575
Flap opened, n (%) 13 (46.4) 5 (29.4) 0.3513
Bone removal, n (%) 7 (25.0) 4 (23.5) 1.0000
Numberof LA carpules
(mean ± SD)
2.36 ± 0.9 2.09 ± 0.78 0.2935
Oral sedation (20mg of
diazepam), n (%)
7 (25.0) 7 (41.2) 0.3262
Preoperative GTN, n (%) 1 (3.6) 0 (0.0) 1.0000
Antibiotic cover, n (%) 5 (17.6) 1 (5.9) 0.3846
• Medications
Single antiplatelets, n (%) 14 (50.0) 8 (47.1) 1.0000
Dual antiplatelets, n (%) 1 (3.6) 2 (11.8) 0.5471
Beta-blockers, n (%) 16 (57.1) 8 (47.1) 0.5521
Statins, n (%) 17 (60.7) 9 (52.9) 0.5754
Ezetimibe, n (%) 2 (7.1) 3 (17.7) 0.3590
Warfarin, n (%) 10 (35.7) 2 (11.8) 0.0962
ACE inhibitors, n (%) 15 (53.6) 8 (47.1) 0.7631
Calcium-channel blockers,
n (%)
5 (17.6) 4 (23.5) 0.7109
Nitrates, n (%) 4 (14.3) 1 (5.9) 0.6343
Cardiac glycosides, n (%) 2 (7.1) 2 (11.8) 0.6262
Proton-pump inhibitors,
n (%)
2 (7.1) 5 (29.4) 0.0858
Diuretics, n (%) 12 (42.9) 4 (23.5) 0.2187
ARBs, n (%) 2 (7.1) 1 (5.9) 1.0000
Oral hypoglycemics, n (%) 4 (14.3) 6 (35.3) 0.1434
Insulin, n (%) 1 (3.6) 0 (0.0) 1.0000
Seretide inhaler, n (%) 1 (3.6) 1 (5.9) 1.0000
Anticholinergics, n (%) 2 (7.1) 1 (5.9) 1.0000
Beta-2 agonists, n (%) 3 (10.7) 2 (11.8) 1.0000
Antiepileptics, n (%) 1 (3.6) 2 (11.8) 0.5471
Antidepressants, n (%) 3 (10.7) 2 (11.8) 1.0000
ACE inhibitors angiotensin-converting enzyme inhibitors, ARBS angioten-
sin receptor blockers, BMI body mass index, COPD chronic obstructive
pulmonary disease, GTN glyceryl trinitrate, LA local anesthetic
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increased hs-TnT levels. It also confirmed that exodontia is also
associated with a rise in bacterial LPS endotoxin and acute
systemic inflammation. These changes were similar in both
patients with and without CAD, although the changes in systemic
inflammation and endotoxemia were more pronounced in those
with a rise in hs-TnT. As consequences of bacteremia and local
trauma and tissue injury, these changes suggest a possible
connection between these mechanisms and minor myocardial
injury following dental surgery as summarized in Fig. 3.
Several limitations should be considered in this study. First,
most of the studied patients were older males (mean age of 69 ±
12 years) with some form of vascular diseases. Indeed, the non-
CAD patients may still have a non-obstructive CAD with a
considerable degree of inflammatory atherosclerosis, which
possibly explains the lack of significant difference between the
groups. Future studies should recruit more patients and include a
greater proportion of females, younger subjects, and healthy
controls (disease free). Second, the presence of several confound-
ing factors, such as sedation, extent of dental extraction, use of
antibiotic prophylaxis, and the use of preoperative GTN could
have influenced our results. These factors could have masked an
expected significant difference between the groups and between
the time points of the biomarkers examined. Such confounding
factors should be taken into account in future studies. Third, the
study did not include early samples following dental extraction,
resulting in a lack of evidence of an early rise of various
inflammatory markers (such as IL-1β, TNF-α, and P-selectin).
Future studies should thus include earlier sampling methods to
characterize the kinetics of the immediate (6–12-h) host response.
An additional limitation is the lack of any microbial (bacterial)
serum/plasma quantification to assess whether the alterations
seen were also correlated with the level of circulating bacterial
endotoxins (which represent mainly the gut rather than oral
microflora activity). Nevertheless, this is the first study to propose
a number of plausible mechanisms, including minor myocardial
injury, as assessed by increased hs-TnT levels as a possible link
between invasive dental treatment and acute cardiovascular
events.
Table 5. Mean levels of biomarkers of all study patients and of patients with and without hs-TnT rise at the three time points (pre, post, and day 1)
Biomarker hs-TnT rise patientsa hs-TnT non-rise patientsb
Pre Post Day 1 Pre Post Day 1
• Biomarkers of systemic inflammation
hs-CRP (mg/L) 5.43 ± 1.03 5.14 ± 0.97 10.53 ± 1.99 2.07 ± 0.50 2.03 ± 0.49 8.31 ± 2.02
Fibrinogen (mg/l) 3.34 ± 0.63 3.29 ± 0.62 3.64 ± 0.69 3.22 ± 0.78 3.13 ± 0.76 3.38 ± 0.82
IFN-γ (pg/ml) 2.35 ± 0.44 2.38 ± 0.45 8.69 ± 1.64 2.37 ± 0.58 2.44 ± 0.59 5.78 ± 1.40
TNF-α (pg/ml) 10.97 ± 2.07 10.44 ± 1.97 12.15 ± 2.30 9.77 ± 2.37 10.09 ± 2.45 10.09 ± 2.45
IL-1β (pg/ml) 0.50 ± 0.09 0.42 ± 0.08 0.41 ± 0.08 0.33 ± 0.08 0.35 ± 0.08 0.57 ± 0.14
IL-6 (pg/ml) 2.02 ± 0.38 1.89 ± 0.36 3.92 ± 0.74 1.88 ± 0.46 1.89 ± 0.46 3.91 ± 0.95
IL-8 (pg/ml) 4.71 ± 0.89 5.37 ± 1.02 6.88 ± 1.30 3.50 ± 0.85 5.88 ± 1.43 5.90 ± 1.43
IL-10 (pg/ml) 6.63 ± 1.25 6.65 ± 1.26 7.23 ± 1.37 9.91 ± 2.41 10.97 ± 2.66 10.66 ± 2.59
IL-12 (pg/ml) 4.30 ± 0.81 4.02 ± 0.76 5.03 ± 0.95 12.33 ± 2.99 11.46 ± 2.78 11.45 ± 2.78
• Biomarker of endotoxemia (LPS endotoxin)
LPS (LAL) (EU/ml) 0.98 ± 0.19 1.09 ± 0.21 1.44 ± 0.27 1.08 ± 0.26 1.10 ± 0.27 1.36 ± 0.33
IL interleukin, IFN-γ interferon-γ, hs-TnT highly sensitive troponin T, hs-CRP highly sensitive C-reactive protein, LPS lipopolysaccharide, TNF-α tumor necrosis
factor-α
Values=mean ± SEM
an= 28 for all except for fibrinogen= 27
bn= 17 for all except for fibrinogen= 16
Table 6. Hierarchical ANOVA and post hoc Bonferroni comparisons
performed on hs-TnT, fibrinogen, TNF-α, LPS, and on hs-CRP, IFN-γ, IL-
1β, IL-6, IL-8 after logarithmic transformation, and IL-12 after square





time points using post hoc
Bonferronib
Groupc Timed Group ×
timee
Pre–Postf Pre-D1g Post-D1h
• Biomarkers of systemic inflammation
hs-CRP log 0.139 <0.001 0.994 >0.999 <0.001 <0.001
Fibrinogen 0.352 0.012 0.812 >0.999 0.037 0.005
IFN-γ log 0.667 <0.001 0.176 >0.999 <0.001 <0.001
TNF-α 0.434 0.096 0.138 >0.999 0.123 0.034
IL-6 log 0.697 <0.001 0.811 >0.999 <0.001 <0.001
IL-8 log 0.404 <0.001 0.652 0.028 <0.001 0.011
IL-12 sqrt 0.434 <0.001 0.218 >0.999 <0.001 <0.001
• Biomarker of endotoxemia (LPS endotoxin)
LPS(LAL) 0.888 <0.001 0.356 0.647 <0.001 <0.001
IL interleukin, IFN-γ interferon-γ, hs-TnT highly sensitive troponin T, hs-CRP
highly sensitive C-reactive protein, LPS lipopolysaccharide, TNF-α tumor
necrosis factor-α
aHierarchical ANOVA at a significance level of 0.025 performed on
biomarkers that were found significant at the 0.05 level by paired t-test
after logarithmic or square root transformation
bPost hoc Bonferroni comparisons made to compare mean values at
different time points of the ANOVA
at a significance level of 0.025 (significant difference shown in red)
cGroup= comparing hs-TnT rise vs. non-rise patients
dTime= comparing the different time points (pretreatment, immediately
post treatment, and day-1 treatment)
eGroup × time= comparing the interaction between the groups and
time points
fPre–Post= comparing pretreatment and immediately post treatment
gPre-D1= comparing pretreatment and day-1 treatment
hPost-D1= comparing immediately post treatment and day-1 treatment
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Simple dental extractions were associated with potential minor
myocardial injury in the form of increased hs-TnT levels in both
patients with and without CAD, representing a possible link
between invasive dental treatment and increased risk of acute
cardiovascular events. Exodontia was also associated with acute
systemic inflammation and endotoxemia, independent of age,
gender, associated diseases and risk factors, dental procedure, or
medication differences. These changes were more evident in
those patients with hs-TnT rise. If replicated in larger studies, the
present observations indicate that invasive dental treatment (as
simple as a single dental extraction) could negatively affect upon
the myocardial health of dental patients, especially those with
CAD.
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